Explained variation in shared frailty models
暂无分享,去创建一个
[1] Heterogeneity in disease free survival between centers: lessons learned from an EORTC breast cancer trial , 2006, Clinical trials.
[2] David V Glidden,et al. Modelling clustered survival data from multicentre clinical trials , 2004, Statistics in medicine.
[3] E. Lesaffre,et al. An application of Harrell's C‐index to PH frailty models , 2010, Statistics in medicine.
[4] R. Porcher,et al. Permutation tests for centre effect on survival endpoints with application in an acute myeloid leukaemia multicentre study , 2014, Statistics in medicine.
[5] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[6] Alicja R. Rudnicka,et al. Measures to assess the prognostic ability of the stratified Cox proportional hazards model , 2009, Statistics in medicine.
[7] J. Concato,et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.
[8] M. Schemper,et al. Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.
[9] R. Gray. Tests for Variation over Groups in Survival Data , 1995 .
[10] Michael W Kattan,et al. Evaluating a New Marker’s Predictive Contribution , 2004, Clinical Cancer Research.
[11] F. Vaida,et al. Proportional hazards model with random effects. , 2000, Statistics in medicine.
[12] R Crouchley,et al. A comparison of frailty models for multivariate survival data. , 1995, Statistics in medicine.
[13] P. Janssen,et al. Understanding Heterogeneity in Generalized Mixed and Frailty Models , 2005 .
[14] T Hielscher,et al. On the prognostic value of survival models with application to gene expression signatures , 2010, Statistics in medicine.
[15] John O'Quigley,et al. Proportional hazards models with frailties and random effects , 2002, Statistics in medicine.
[16] M. Schemper. The relative importance of prognostic factors in studies of survival , 1993 .
[17] N Keiding,et al. Individual survival time prediction using statistical models , 2005, Journal of Medical Ethics.
[18] Matthias Schmid,et al. A comparison of estimators to evaluate the discriminatory power of time‐to‐event models , 2012, Statistics in medicine.
[19] Catherine Legrand,et al. The shared frailty model and the power for heterogeneity tests in multicenter trials , 2002 .
[20] Janez Stare,et al. A note on bias of measures of explained variation for survival data. , 2016, Statistics in medicine.
[21] M. Gnant,et al. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer , 2005, British Journal of Cancer.
[22] R. Xu,et al. Three measures of explained variation for correlated survival data under the proportional hazards mixed‐effects model , 2016, Statistics in medicine.
[23] John O'Quigley,et al. Explained randomness in proportional hazards models , 2005, Statistics in medicine.
[24] Patrick Royston,et al. A simulation study of predictive ability measures in a survival model I: Explained variation measures , 2012, Statistics in medicine.
[25] M. Schemper,et al. Statistical controversies in clinical research: the importance of importance. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[27] J P Klein,et al. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.